Oocyte cryopreservation as a fertility preservation measure for cancer patients

Noyes, N.; Knopman, J.M.; Melzer, K.; Fino, Mary Elizabeth; Friedman, Bruce J.; Westphal, Lynn M.

doi:10.1016/j.rbmo.2010.11.011

Cited by 69 publications

(37 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Quick-start strategies [23] including pre-treatment with a GnRH antagonist were utilized in 21 patients (mean age 33±6y) with favorable cycle outcomes. In nine of these cycles, patients received a one-time 3 mg dose (preferable, but expensive) while in 21 cycles, a 250 μg dose was administered for 3 consecutive days.…”

Section: Cycle Outcomesmentioning

confidence: 99%

Experiences in fertility preservation: lessons learned to ensure that fertility and reproductive autonomy remain options for cancer survivors

Noyes¹,

Melzer²,

Druckenmiller³

et al. 2013

J Assist Reprod Genet

Self Cite

View full text Add to dashboard Cite

Purpose Assess fertility preservation (FP) measures chosen by patients newly diagnosed with malignancy and their outcomes. Methods Reproductive-age patients referred for FP underwent counseling and elected cryopreservation vs. no treatment. Outcome measures included ovarian stimulation, FP choice, oocytes/zygotes retrieved/cryopreserved and pregnancy outcome.Results From 2005 to 2012, 136 patients were counseled with 124 electing treatment: 83 oocyte-only, 21 oocyte+zygote and 20 zygote-only cryopreservation. Age, partnership and financial status factored into FP choice. Treatment was completed in 12±2 days with 14±11 metaphase-II oocytes harvested and cryopreserved/cycle. Eight patients returned to attempt pregnancy; three succeeded. Conclusions Our data demonstrate that oocyte and/or zygote banking are feasible FP options for women with malignancy; given the choice, the majority elected oocyte cryopreservation, highlighting desire for reproductive autonomy. Continued growth and research, combined with interdisciplinary communication, will ensure that appropriate candidates are offered FP and the potential for future parenthood, an important quality-oflife marker for survivors.

show abstract

Section: Cycle Outcomesmentioning

confidence: 99%

Experiences in fertility preservation: lessons learned to ensure that fertility and reproductive autonomy remain options for cancer survivors

Noyes¹,

Melzer²,

Druckenmiller³

et al. 2013

J Assist Reprod Genet

Self Cite

View full text Add to dashboard Cite

show abstract

“…These encouraging results suggest that oocyte vitrification can be largely used for a panel of purposes including oocyte storing in cases of sperm retrieval failure [19], fertility preservation [20] or egg donation [3,13].…”

Section: Discussionmentioning

confidence: 96%

Oocyte vitrification: A local validation of the method

Boyer¹,

Montjean²,

Tourame³

et al. 2013

OJOG

View full text Add to dashboard Cite

Is there a really need to validate oocyte vitrification technique in an ART laboratory before establishing it in daily practice? Validation of micromanipulationbased technique, in this case oocyte vitrification, is essential prior to enlarging its use to routine practice. Oocyte vitrification is a new worldwide used technique and legal recently in France. This micromanipulation needs to be performed by a skilled and experienced embryologist and requires an internal assessment in each ART unit before any wide use. We designed a prospective study, from September 2011 to July 2012, using sibling oocytes from women who recovered more than 12 Metaphase II oocytes. A part of freshly recovered oocytes underwent immediate ICSI while the remaining oocytes were vitrified. 87 couples undergoing ICSI were selected based on number of mature oocytes available on the recovery day after denudation. A part of fresh MII oocytes were microinjected and the others were vitrified using an open system (Cryotop ® ). The major criterion of interest was the number of embryo transferred/ number of Metaphase II ratio for after ICSI on fresh oocytes (42/211) versus vitrified/warmed oocytes (51/204) (p > 0.05). Secondary studied criteria were survival rate (80.5% ± 26.3%), fertilization rate (68.9 ± 33.5) and finally, cumulative pregnancy rate obtained in this study is 40.2%. One of the benefits of such practice is the limitation of embryo freezing. However, the study design delays oocytes warming cycles, due to pregnancies triggered by the transfer of fresh derived oocyte embryos and to the priority to transfer all the frozen embryos before starting oocytes warming. Moreover, no data is available about children' health. Oocyte vitrification represents not only a change in our daily practice to improve cumulative pregnancy rate but also a promising tool to develop egg banking and donation. Clinical Trials Registration number: 209 R02.

show abstract

“…The difficulties of preserving oocyte structural and functional integrity were significantly greater than those encountered in the freezing of embryos, in part because of the high volume-to-surface ratio of oocytes and inherent problems with the formation of ice crystals that easily damage the cell membrane and internal structures. Improvements in cooling techniques, cryoprotectants, and protocols have since dramatically improved oocyte survival and pregnancy rates [18][19][20] . The introduction and refinement of vitrification has minimized structural damage to oocytes and has improved survival rates, currently in the range 87%-97% (about a 15% improvement compared with slow freezing) 17,21 .…”

Section: Oocyte Cryopreservation With Ovarian Stimulationmentioning

confidence: 99%

“…In patients who are time-limited and unable to postpone their gonadotoxic cancer treatment for 2 weeks, ivm with or without ovarian tissue extraction is a suitable option 19 . Finally, ivm of oocytes aspirated from antral follicles of harvested ovarian tissue may be an option for prepubertal females.…”

Section: Ivmmentioning

confidence: 99%

“…The method also avoids ovarian stimulation and the passage of protracted amounts of time before chemotherapy can begin 8 . Additional advantages include the possibility that primordial follicles within the ovarian tissue are more resistant to cryopreservation than are oocytes themselves 19 . A much larger pool of oocytes and follicles may also be available for preservation than would be the case in oocyte aspiration 33 .…”

Section: Ovarian Tissue Cryopreservation and Transplantationmentioning

confidence: 99%

See 1 more Smart Citation